Page last updated: 2024-12-05
3'-methylacetanilide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3'-methylacetanilide: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 10843 |
| CHEMBL ID | 1528164 |
| SCHEMBL ID | 12133 |
| MeSH ID | M0527685 |
Synonyms (65)
| Synonym |
|---|
| unii-ky86r0888b |
| ky86r0888b , |
| LS-13628 |
| 537-92-8 |
| 3-methylacetanilide |
| m-acetotolidide |
| n-acetyl-3-methylaniline |
| 1-acetamido-3-methylbenzene |
| wln: 1vmr c1 |
| m-methylacetanilide |
| 3'-methylacetanilide |
| nsc-3103 |
| n-acetyl-m-toluidine |
| m-acetotoluidide |
| 3-acetamidotoluene |
| aceto-m-aminotoluene |
| m-tolylacetamide |
| nsc3103 |
| m-acetotoluide |
| acetamide, n-(3-methylphenyl)- |
| n-m-tolylacetamide |
| n-(3-methylphenyl)acetamide |
| inchi=1/c9h11no/c1-7-4-3-5-9(6-7)10-8(2)11/h3-6h,1-2h3,(h,10,11 |
| NCGC00091308-01 |
| acetotoluide |
| einecs 208-678-1 |
| nsc 3103 |
| n-acetyl-n-toluidine |
| n-acetoxy-3-toluidine |
| ai3-16907 |
| ccris 5955 |
| STK301244 |
| 3'-methylacetanilide, 98% |
| A0062 |
| m-acetotoluidine |
| smr001370913 |
| MLS002415752 |
| AKOS003870217 |
| NCGC00091308-02 |
| HMS3039L06 |
| dtxsid6024412 , |
| tox21_200887 |
| cas-537-92-8 |
| dtxcid304412 |
| NCGC00258441-01 |
| n1-(3-methylphenyl)acetamide |
| 3-acetylaminotoluene |
| m-methyl acetanilide |
| FT-0616116 |
| AB01179 |
| acetyl-m-toluidine, n- |
| m-acetotoluide [mi] |
| SCHEMBL12133 |
| mfcd00014962 |
| W-105708 |
| n-(3-tolyl)acetic acid amide |
| meta-acetotoluidide |
| CHEMBL1528164 |
| n-acetyl-meta-toluidine |
| CS-0204499 |
| Q27282500 |
| ethyl3-(trifluoromethyl)-1,2,4-oxadiazole-5-carboxylate |
| D88205 |
| 3 inverted exclamation mark -methylacetanilide |
| SY081519 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (13)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 31.6228 | 0.0251 | 20.2376 | 39.8107 | AID886 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 80.0307 | 0.0072 | 15.7588 | 89.3584 | AID1224835 |
| AR protein | Homo sapiens (human) | Potency | 68.8687 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 30.7625 | 0.0010 | 22.6508 | 76.6163 | AID1224838 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 43.4532 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 28.2535 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 73.0704 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID743080 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 6.3096 | 0.0237 | 23.2282 | 63.5986 | AID588543 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0007 | 0.0100 | 39.5371 | 1,122.0200 | AID588547 |
| geminin | Homo sapiens (human) | Potency | 0.1636 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 77.2720 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 77.2720 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Ceullar Components (1)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| plasma membrane | Glutamate receptor 2 | Rattus norvegicus (Norway rat) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (28.57) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 19.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.83) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||